United States Viral Vector Manufacturing Market Set for Strong

The Viral Vector Manufacturing Market reached a value of USD 0.9 billion in 2022 and is projected to grow to USD 3.8 billion by 2031, representing a compound annual growth rate (CAGR) of 20.3% from 2024 to 2031. The sector focuses on producing viral vectors, which are engineered viruses used for delivering genetic material in applications such as gene therapy, cell therapy, and vaccine development. The market includes production through contract manufacturing, in-house production, and advanced technologies for biopharmaceutical uses, as highlighted in a report by DataM Intelligence.

Recent developments include significant activities in the United States and Japan. In August 2025, ProBio launched cGMP Adeno-Associated Virus (AAV) manufacturing services in New Jersey. In Japan, Takeda Pharmaceutical introduced a new AAV-based gene therapy for rare metabolic disorders in September 2025. Additionally, Mitsubishi Tanabe Pharma invested ¥15 billion in a new gene therapy manufacturing facility in Osaka.

Key players in the Viral Vector Manufacturing Market include Sanofi SA, Thermo Fisher Scientific Inc., and Merck & Co.

• Why it matters: This growth indicates increasing investment and innovation in gene and cell therapies, crucial for addressing various diseases.
• This expansion could lead to enhanced manufacturing capabilities and reduce costs, making therapies more accessible to patients.
• The latest: Takeda Pharmaceutical’s recent launch of an AAV-based gene therapy is expected to boost demand for commercial-scale AAV vector production.